Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. (AKBA) reports corporate governance changes effective April 3, 2020, and April 6, 2020. The company is a Delaware corporation headquartered in Cambridge, Massachusetts, with common stock traded on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation arrangements.
Material Changes
- Board Resignation: Jodie P. Morrison resigned from the Board of Directors and the Research & Development (R&D) Committee on April 3, 2020. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Board Election: On April 6, 2020, the Board elected Myles Wolf, M.D., M.S.Sc., as a Class II director to fill the vacancy left by Ms. Morrison. His term expires at the 2022 annual meeting.
- Committee Appointment: Dr. Wolf was appointed to the R&D Committee and determined to be an independent director under Nasdaq Listing Rule 5605(a)(2).
Compensation and Governance Details
Dr. Wolf's compensation is governed by the Company's Amended and Restated Non-Employee Director Compensation Program:
- Cash Retainers: $45,000 annually for Board service and $5,000 annually for R&D Committee service.
- Equity Grants: Annual grants of 20,100 stock options and 13,700 restricted stock units (RSUs).
- Initial Grant: On April 6, 2020, Dr. Wolf received an initial grant of 80,200 stock options.
- Indemnification: Dr. Wolf receives the same indemnification rights as other non-employee directors.
Investor Verification Checklist
- Verify the independence status of Dr. Wolf under Nasdaq rules.
- Confirm the total number of outstanding options and RSUs granted to Dr. Wolf in the company's latest equity compensation filings.
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial metrics.
- Check for any subsequent filings regarding the status of the R&D Committee following the personnel changes.